^“A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage”. Nature404 (6773): 42–9. (March 2000). doi:10.1038/35003506. PMID10716435.
^“A ribonucleotide reductase gene is a transcriptional target of p53 and p73”. Oncogene19 (37): 4283–9. (August 2000). doi:10.1038/sj.onc.1203774. PMID10980602.
^“Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion”. Nature Genetics39 (6): 776–80. (June 2007). doi:10.1038/ng2040. PMID17486094.
^“A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy”. Molecular Genetics and Metabolism98 (3): 300–4. (November 2009). doi:10.1016/j.ymgme.2009.06.012. PMID19616983.
^“Novel RRM2B Mutation and Severe Mitochondrial DNA Depletion: Report of 2 Cases and Review of the Literature”. Neuropediatrics. (May 2017). doi:10.1055/s-0037-1601867. PMID28482374.
^“Deep Sequencing Reveals Novel Genetic Variants in Children with Acute Liver Failure and Tissue Evidence of Impaired Energy Metabolism”. PloS One11 (8): e0156738. (2016). doi:10.1371/journal.pone.0156738. PMID27483465.
^“Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma”. Journal of Hepato-Biliary-Pancreatic Sciences18 (5): 700–11. (September 2011). doi:10.1007/s00534-011-0376-7. PMID21451941.
“Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells”. The Journal of Biological Chemistry276 (44): 40647–51. (November 2001). doi:10.1074/jbc.M106088200. PMID11517226.
“p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint”. Cancer Research61 (22): 8256–62. (November 2001). PMID11719458.
“Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma”. Cancer Letters190 (2): 233–43. (February 2003). doi:10.1016/S0304-3835(02)00588-8. PMID12565178.
“Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits”. Cancer Research63 (5): 980–6. (March 2003). PMID12615712.
“The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53”. Cancer Research63 (20): 6583–94. (October 2003). PMID14583450.
“In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase”. Cancer Research64 (1): 1–6. (January 2004). doi:10.1158/0008-5472.CAN-03-3048. PMID14729598.
“Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes”. Oncogene24 (28): 4559–71. (June 2005). doi:10.1038/sj.onc.1208652. PMID15856024.
“Novel genetic variations of the p53R2 gene in patients with colorectal adenoma and controls”. World Journal of Gastroenterology11 (33): 5169–73. (September 2005). PMID16127747.
“Genotoxicity test system based on p53R2 gene expression in human cells: examination with 80 chemicals”. Mutation Research588 (1): 47–57. (December 2005). doi:10.1016/j.mrgentox.2005.09.002. PMID16236544.
“Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits”. Biochemical and Biophysical Research Communications340 (2): 428–34. (February 2006). doi:10.1016/j.bbrc.2005.12.019. PMID16376858.
“Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma”. Clinical Cancer Research12 (12): 3740–5. (June 2006). doi:10.1158/1078-0432.CCR-05-2416. PMID16778101.
“Effect of high-risk human papillomavirus oncoproteins on p53R2 gene expression after DNA damage”. Virus Research122 (1-2): 189–93. (December 2006). doi:10.1016/j.virusres.2006.06.011. PMID16872707.
“Improvement in radiosensitivity using small interfering RNA targeting p53R2 in esophageal squamous cell carcinoma”. Oncology Reports18 (3): 561–7. (September 2007). doi:10.3892/or.18.3.561. PMID17671702.